Novo planning regulatory submission after rFXIII data

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) plans to submit a regulatory application to FDA for rFXIII next half after reporting data from the Phase III Mentor 1 trial to prevent bleeding episodes associated...